TMEM97 and glioblastoma: Exciting new frontiers for PET imaging targets for GBM include PD-L1 for immune status, PARP-1 for DNA damage, sigma 2 receptors as alternative markers of proliferation, and isocitrate dehydrogenase for tumorigenesis activity.